emyria

ASX : EMD

Quarterly Update for the period ended 30 September

Quarterly Webinar



Important notice and disclaimer

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This presentation may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", "estimates", "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this presentation. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking 2statemEemntsyrtiao r|efUleSctInevveesntotsr, Rciorcaudmshsotawnc|esOocrtoubnearn2ti0c2ip6ated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

United States. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Emyria's securities have not been, and will not be, registered under the US Securities Act of 1933, as amended, or the securities laws of any state of the United States, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, those registration requirements.

Currency. All amounts are in Australian dollars (A$) unless stated otherwise. US dollar (US$) equivalents are provided for convenience only, at A$1.00 = US$0.69 (Reserve Bank of Australia, 2 October 2026).

emyria

Who are we?

Clinics across four states

5

Treatment beds

18

Clinician Workforce (APs+therapists)

~145

Patients treated

>160

FY26 revenue, up 191%

A$4.05m

emyria

ASX: EMD

Building a National network of specialty mental health clinics

Treating **PTSD** and **treatment-resistant depression**



1) Patients, clinics, beds and revenue as reported for FY26 See ASX announcement 8 September 2026

Advanced therapies. Compassionate care.


Worldwide first mover advantage

A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions

Australia


is the FIRST jurisdiction in the world to reschedule two promising treatments[1]

MDMA-assisted therapy



For PTSD

Psilocybin-assisted therapy



For Depression

This regulation change has created a Significant Market Opportunity.

Significant Total Addressable Market

~1.5M adults in Australia have **PTSD** (~7%)[1]

~1.1M adults in Australia have **Major Depression** (~4%)[1]

SOURCES

1 .https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrist

2 1).https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statisticss

Major Funders are Spending Millions Annually

Reimbursement has commenced for Psychedelic Assisted Therapy

Private Health Insurers

$2B **($219M/yr in 2024 alone)** [1]

Spent by Medibank on mental health hospitalisations in last 10 years [2]

$100M

Total recent investment from Medibank into the **future of mental health,** with $50M committed over the next five years [3]

Department of Veterans' Affairs

The Government spends

$300M/yr on veteran mental health each year [4]

25% of ADF personnel currently considered unfit to deploy [5]

13% of personnel deemed unfit to deploy classified as being in **"rehabilitation"** [6]

Other Insurers

Life insurers paid out more than

$2.4B in 2024

for retail mental health claims [7]


90% of HCF's open gold-tier claims are for mental health issues [8]

18% increase in average private health insurance benefit over last **five** years [9]

SOURCES:
1. https://www.heraldsun.com.au/health/mental-health/alarming-research-shows-extent-of-mental-health-crisis-in-australia/news-story/66f6937a316f9dd54673c5a6f692b232
2, 3. https://www.medibank.com.au/livebetter/newsroom/post/medibank-group-marks-50-years-with-additional-50m-mental-health-investment-taking-total-to-100m
4. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf
5, 6. https://www.theaustralian.com.au/nation/defence/onequarter-of-adf-personnel-not-medically-fit-to-deploy-senate-estimates-told/news-story/3b2e26b4930cecb3575c237ea0b65d1d
7. https://www.abc.net.au/news/2025-07-16/spike-in-mental-health-illness-claims-super-funds-delay-payouts/105531022
8, 9. https://www.afr.com/companies/healthcare-and-fitness/hcf-says-soaring-mental-health-claims-driving-up-premiums-20261019-p614zz

Patient journey I Treatment model + bed capacity

Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up



BED CAPACITY		
Clinic	**Beds**	**Dosing days / week**
Perth (x2)	8	40
Brisbane	3	15
Melbourne	3	15
Sydney	4	20
=	**18**	**90**

~A$10k

Revenue per dosing day

~A$33k

Total per PTSD course (3 dosing days)

~A$22k

Total per TRD course (2 dosing days)

Maturing clinic I Perth Clinic dosing days May 2025 to June 2026

Clinic Capacity 80 dosing days / month



SOURCES:
1. See ASX announcement 11 June 2026

* Monthly stand alone clinic breakeven.

Quarterly Highlights

This quarter has seen major developments for EMD

Opening of first Sydney Clinic

NSW clinic opened in September 2026, expanding the company's footprint to four states, increasing national treatment capacity to up to 90 dosing sessions per week.



Unlocked clinician capacity

Additional Authorised Prescriber availability in Perth (2) & Brisbane (3) clinics to enable greater dosing capacity; increased therapist recruitment and training (15) to meet TGA therapist requirements in Perth.



Appointment of Strategic Advisor

Former US Secretary of Veterans Affairs Dr David Shulkin appointed as Strategic Advisor, to help explore US opportunities. Webinar interview recorded with Secretary Shulkin & Executive Chair Greg Hutchinson.



Presentation at FDA Hearing

Executive Chair Greg Hutchinson was invited to present in person to US regulators at the US FDA public hearing on the future of psychedelic medicines.



Record Quarterly Revenue of


$1.42m

First cohort of DVA approvals received,

40+ referrals in pipeline

Momentum in Psychedelic Medicine Sector Continues to Build

Recent macro catalysts provide significant tailwinds for Emyria




















A new era is unfolding in psychedelic medicine – first-mover Emyria is well positioned to take advantage of the opportunities that are arising

Emyria | Looking Ahead

Delivering on commitments to shareholders

Core focus areas:

- Starting first DVA-funded treatments for veterans
- Pursuing US commercial and partnership opportunities supported by Strategic Advisor Dr David Shulkin
- Growing referrer education and increasing use of Empax network capacity
- Leveraging our clinical infrastructure, treatment delivery expertise and real-world evidence to support future international commercial opportunities

Investor Q+A

Greg Hutchinson

ghutchinson@emyria.com

Mary-Ann Rennie

mrennie@emyria.com

Investor / Media Inquiries

investors@emyria.com

emyria

Visit Our Investor Hub